7024-58-0

Basic information

• Product Name: 2-Cyclopropylpyrimidine-4,6-diol
• Synonyms: 2-Cyclopropylpyrimidine-4,6-diol
• CAS NO: 7024-58-0
• Molecular Formula: C7H8N2O2
• Molecular Weight: 152.15062
• Mol File: 7024-58-0.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Cyclopropylpyrimidine-4,6-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Cyclopropylpyrimidine-4,6-diol(7024-58-0)
• EPA Substance Registry System: 2-Cyclopropylpyrimidine-4,6-diol(7024-58-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 7024-58-0(Hazardous Substances Data)

Upstream product

• 57297-29-7 cyclopropylcarboxamidine hydrochloride 
• 108-59-8 malonic acid dimethyl ester 
• 105-53-3 diethyl malonate 
• 108-13-4 malonodiamide 
• 4606-07-9 ethyl cyclopropylcarboxylate 
• 54070-74-5 cyclopropanecarboxamidine 

Downstream Products

• 1305117-30-9 N₄-{[(2S)-4-benzylmorpholin-2-yl]methyl}-6-chloro-2-cyclopropylpyrimidine-4,5-diamine 
• 1305117-31-0 3-{[(2R)-4-benzylmorpholin-2-yl]methyl}-7-chloro-5-cyclopropyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine 
• 1305115-67-6 3-{[(2R)-4-benzylmorpholin-2-yl]methyl}-5-cyclopropyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-amine 
• 70058-41-2 2-Cyclopropyl-4-hydroxy-6-methoxypyrimidin 
• 75438-78-7 2-cyclopropyl-4,6-dichloro-5-nitro-pyrimidine 
• 7043-09-6 4,6-dichloro-2-cyclopropylpyrimidine 
• 75438-77-6 2-cyclopropyl-4,6-dihydroxy-5-nitro-pyrimidine 
• 811802-33-2 2-cyclopropyl-4,6-diisopropoxypyrimidine 

Relevant articles and documents

PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS

The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Discovery of triazolopyrimidine-based PDE8B inhibitors: Exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes

PDE8B is a cAMP-specific isoform of the broader class of phosphodiesterases (PDEs). As no selective PDE8B inhibitors had been reported, a high throughput screen was run with the goal of identifying selective tools for exploring the potential therapeutic utility of PDE8B inhibition. Of the numerous hits, one was particularly attractive since it was amenable to rapid deconstruction leading to inhibitors with very high ligand efficiency (LE) and lipophilic ligand efficiency (LLE). These triazolopyrimidines were optimized for potency, selectivity and ADME properties ultimately leading to compound 42. This compound was highly potent and selective with good bioavailability and advanced into pre-clinical development.

Discovery of a potent nicotinic acid receptor agonist for the treatment of dyslipidemia

Nicotinic acid has been used clinically for decades to control serum lipoproteins. Nicotinic acid lowers very low-density lipoprotein (VLDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, and lipoprotein-a (LPa), and it is also effective in raising high-density lipoprotein (HDL)-cholesterol. However, nicotinic acid has several side effects in clinical use. The most notable is intense cutaneous vasodilation "flushing"+ on the upper body and face. We discovered a pyranopyrimidinedione series to be nicotinic acid receptor agonists. A potent nicotinic acid receptor agonist from this series {5-(3-cyclopropylpropyl)-2-(difluoromethyl)-3H-pyrano[2,3-d] pyrimidine-4,7-dione}with reduced flushing side effect in dogs was identified.